5.5 million people, EEA pharmaceutical regulatory alignment, Europe's highest multiple sclerosis rates, the HUNT Study's 229,000 longitudinal participants, a Cancer Registry since 1953, and petroleum-funded research infrastructure; Norway is Scandinavia's most scientifically distinctive research platform.
Norway is a Nordic constitutional monarchy of approximately 5.5 million people; the wealthiest per-capita country in Scandinavia, with petroleum revenues channelled through the Government Pension Fund Global (the world's largest sovereign wealth fund) into world-class public services including an exceptionally well-funded healthcare and research infrastructure. The country occupies the western Scandinavian peninsula, stretching from the temperate southwest to the High Arctic north, with a coastline exceeding 25,000 km including fjords. Oslo (~700,000; ~1.1 million metropolitan) is the capital and dominant research hub, home to Oslo University Hospital; a national hospital system comprising the Norwegian Radium Hospital (cancer), Rikshospitalet (transplantation, rare diseases), and Ullevål (major general academic hospital). Bergen, Trondheim, and Tromsø are the other three university cities each anchoring their own hospital-based research ecosystems, with Tromsø distinguishing itself globally as the world's northernmost city hosting a full medical university. Norway is a member of the European Economic Area (EEA), the Schengen Area, and NATO; but is not an EU member, a distinction that shapes its pharmaceutical regulatory framework while maintaining equivalence with EU standards through the EEA mechanism.
Clinical trials in Norway are regulated by the Norwegian Medicines Agency (Statens legemiddelverk; NoMA), operating under pharmaceutical legislation aligned with EU directives through the EEA Agreement. NoMA participates actively in EMA scientific committee work and maintains regulatory standards that are functionally equivalent to those of EU member states; Norwegian clinical trial data is accepted in EU regulatory submissions on this basis. Ethics review is provided through Regional Committees for Medical and Health Research Ethics (REK), seven regionally distributed committees covering the country's health regions with a coordinated national standard. Health data access for research is governed by the Norwegian Institute of Public Health (FHI), which maintains and provides research access to Norway's national health registers; the fødselsnummer (national personal identification number) linking every citizen's lifetime health data across all Norwegian healthcare providers and registers in a system structurally comparable to Sweden's personnummer and Denmark's CPR.
Norway's population is approximately 82% Norwegian-born, with growing communities from Poland (~2.1%), Lithuania (~1.1%), Somalia, Pakistan, Sweden, Germany, and other nationalities; a multicultural composition that has grown rapidly since EU enlargement in 2004. Very high English proficiency is universal in the Norwegian research community, and clinical trial documentation, sponsor communication, and investigator collaboration are conducted in English as a matter of course. Educational attainment is among the world's highest, health literacy is exceptional, and the universal healthcare system (managed through four regional health authorities covering the entire population) ensures structured patient access, comprehensive electronic health records, and robust follow-up infrastructure at every research site. The median age is approximately 39–40 years, providing good population depth across a wide range of therapeutic indication age profiles. Norwegian patients are characterised by very high trial compliance and extremely low dropout rates; consequences of the high-trust societal model and the structured patient-physician relationship maintained through universal healthcare.
Norway's disease burden has several features of exceptional clinical research significance. Cardiovascular disease is the leading cause of death (~35% of mortality), with a population cohort research tradition; through the Tromsø Study and HUNT Study; that has generated foundational cardiovascular epidemiology data for decades. Cancer is the second leading cause, with a Cancer Registry active since 1953 enabling 70+ years of continuous national cancer incidence and outcome data. Multiple sclerosis carries a uniquely Norwegian epidemiological dimension: Norway has consistently reported among the world's highest MS prevalence rates, estimated at approximately 200 per 100,000 population; driven by a combination of genetic predisposition, geographic latitude, and vitamin D exposure patterns; creating an MS patient pool of extraordinary depth relative to total population. Neurological and psychiatric disease is well-characterised through comprehensive national registries. Inflammatory and autoimmune conditions, metabolic disease, and musculoskeletal disorders each represent active research areas with strong population cohort underpinning.
Two assets no other Scandinavian market replicates; the HUNT Study and Europe's MS depth: The Trøndelag Health Study (HUNT), anchored at NTNU in Trondheim and St. Olavs Hospital, has enrolled over 229,000 participants from the Trøndelag region; representing approximately 65% of the adult population of the area; in successive waves since 1984, with biological samples, genetic data, cardiovascular measurements, and lifestyle questionnaires enabling multigenerational longitudinal analysis. No comparable regional population biobank in Scandinavia approaches this combination of population coverage and longitudinal depth. Simultaneously, Norway's multiple sclerosis prevalence of approximately 200 per 100,000; among the world's three highest nationally documented rates; means that Norwegian neurologists see MS patient volumes per investigator that are simply unattainable in Germany, France, Italy, or even Sweden. For MS program sponsors, Norway's investigator depth and patient concentration represent a patient recruitment efficiency that cannot be approximated elsewhere in continental Europe.
Norway's research proposition rests on a combination of depth assets unavailable in combination anywhere else in Scandinavia: the world's deepest MS patient pools, a 229,000-participant regional biobank in Trondheim, a Cancer Registry active since 1953, petroleum-funded research infrastructure at per-capita investment levels that match the most generously endowed research nations, and the world's northernmost university hospital creating uniquely positioned Arctic medicine research capability. None of these is shared with Sweden or Denmark in the same form.
EEA pharmaceutical regulatory framework fully aligned with EU CTR standards; NoMA as an experienced, internationally respected NCA with active EMA scientific committee participation; Regional Committees for Medical and Health Research Ethics (REK) providing regionally distributed, nationally consistent review; fødselsnummer register linkage for outcome ascertainment equivalent to EU member state register infrastructure; Norwegian trial data accepted in EU regulatory submissions.
Petroleum revenues channelled through the Norwegian welfare state fund one of Europe's highest per-capita research investments; Research Council of Norway provides substantial grant co-funding for collaborative research programs; national health register-based outcome ascertainment dramatically reduces long-term follow-up costs; costs competitive within the Scandinavian Nordic tier; all four major health regions maintain well-resourced university hospital research departments without the budget constraints of less wealthy European systems.
Europe's highest MS prevalence (~200 per 100,000) creating unmatched investigator-to-patient ratios for neurological trials; HUNT Study's 229,000 longitudinally followed participants with genetic and biological data for NTNU/St. Olavs-based biomarker programs; fødselsnummer enabling lifetime health data linkage across all Norwegian registers; Cancer Registry data since 1953; high patient compliance and near-zero structural dropout through universal healthcare follow-up pathways.
Oslo University Hospital (Radiumhospitalet for cancer; Rikshospitalet for transplant and rare diseases); Haukeland University Hospital for Bergen-region neurology and oncology; NTNU/St. Olavs Hospital anchoring HUNT Study biobank capability; University Hospital of North Norway (UNN) as the world's northernmost full university hospital; NORMENT Centre for psychiatric genetics; Norwegian Arthroplasty Register (world's oldest joint replacement registry, since 1987) for musculoskeletal programs.
Multiple sclerosis is Norway's single most globally distinctive therapeutic research niche: with a prevalence rate among the world's three highest (~200 per 100,000), Norway offers MS investigators and Phase II–III MS sponsors a patient concentration, investigator experience per physician, and national MS Registry data depth that is fundamentally unavailable in larger European markets with lower prevalence. Oslo University Hospital, Haukeland University Hospital, and St. Olavs Hospital are all world-class MS research centres by any international metric. Oncology constitutes the second major pillar, powered by Radiumhospitalet (the Norwegian Radium Hospital); a dedicated national cancer centre of extraordinary historical and contemporary research significance; backed by a Cancer Registry with 70+ years of continuous national data. Cardiovascular disease is Norway's longest-researched area: the Tromsø Study (since 1974) and HUNT Study (since 1984) have provided foundational population cohort data that makes Norwegian cardiovascular investigators among the world's most longitudinally informed. NORMENT, the Norwegian Centre for Mental Disorders Research at Oslo University Hospital, has made Norway a global address for psychiatric genetics and schizophrenia/bipolar research. Musculoskeletal medicine benefits from the world's oldest national arthroplasty registry (since 1987). Arctic medicine; the physiology and pathology of extreme cold exposure, seasonal light variation, and circumpolar health; is a uniquely Norwegian research niche centred on UiT and the University Hospital of North Norway in Tromsø.
Oslo University Hospital; across its Radiumhospitalet, Rikshospitalet, and Ullevål campuses; dominates Norwegian clinical research activity, accounting for the majority of Phase I–III commercial trial volume and effectively serving as the national research anchor for all major therapeutic areas. Haukeland University Hospital in Bergen and St. Olavs Hospital in Trondheim anchor the west and central Norway research corridors respectively, with St. Olavs uniquely positioned as the clinical base for the HUNT Study's participant management and biobank access. The University Hospital of North Norway in Tromsø represents a uniquely positioned Arctic medicine institution whose patient population, geographic isolation, and environmental exposure characteristics create research conditions unavailable at any more southerly European site.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Oslo University Hospital; Norwegian Radium Hospital (Radiumhospitalet) | Oslo | Norway's dedicated national cancer centre and one of Scandinavia's most internationally recognised oncology research institutions; University of Oslo Faculty of Medicine affiliate; Phase I–IV across solid tumours, haematologic malignancies, and radiotherapy-combined indications; houses Norway's primary Phase I oncology unit and the national tumour biobank; one of the founding members of the EORTC network and a longstanding active participant in international oncology cooperative groups; the institutional anchor of Norwegian oncology's global research standing. |
| 02 | Oslo University Hospital; Rikshospitalet | Oslo | Norway's national referral hospital for transplantation, rare diseases, congenital conditions, and specialist surgical procedures; University of Oslo affiliate; Phase II–IV with exceptional depth in solid organ transplantation pharmacology, paediatric rare diseases, congenital cardiac conditions, and haematological malignancies requiring bone marrow transplantation; houses the national paediatric hospital (Rikshospitalet Barneklinikken); a critical site for sponsors in orphan drug development requiring Norway's population-based rare disease patient identification infrastructure. |
| 03 | Oslo University Hospital; Ullevål | Oslo | Oslo University Hospital's primary major general academic campus, covering a broad multispecialty research portfolio; University of Oslo affiliate; Phase II–IV across cardiovascular, neurology, psychiatry, emergency medicine, and internal medicine; home of NORMENT (Norwegian Centre for Mental Disorders Research); one of Europe's leading psychiatric genetics and CNS drug development research centres; the largest clinical trial volume among Oslo University Hospital's campuses for general therapeutic area programs. |
| 04 | Akershus University Hospital (AHUS) | Lørenskog | One of Norway's largest hospitals, serving the Akershus county population immediately surrounding Oslo and one of the most research-active non-capital university hospitals in the country; University of Oslo affiliate; Phase II–IV across oncology, cardiovascular, endocrinology, and internal medicine; a rapidly growing Phase II–III commercial portfolio reflecting sustained investment in research infrastructure; important complement to Oslo University Hospital for sponsors seeking Oslo-region patient volume beyond the three OUS campuses. |
| 05 | Haukeland University Hospital | Bergen | Western Norway's premier academic hospital and the primary clinical base of the University of Bergen Faculty of Medicine; Phase I–IV across oncology, neurology; particularly multiple sclerosis; haematology, cardiovascular, and transplantation medicine; one of Norway's top two MS research centres with a large, well-characterised MS patient cohort; active EORTC and international cooperative group participation; home of the K.G. Jebsen Centres for MS Research and for Brain Tumours reflecting Bergen's particular specialist research depth in neurological oncology. |
| 06 | St. Olavs Hospital (St. Olav's University Hospital) | Trondheim | Central Norway's university hospital and the clinical base of NTNU Faculty of Medicine and Health Sciences; Phase II–IV across cardiovascular, oncology, neurology, endocrinology, and psychiatry; uniquely positioned as the anchor institution for the HUNT Study; giving St. Olavs investigators access to longitudinal data and biological samples from 229,000+ Trøndelag region participants for biomarker sub-studies, pharmacogenomics programs, and population-linked outcome ascertainment that is unmatched at any other Scandinavian clinical research site. |
| 07 | University Hospital of North Norway (UNN) | Tromsø | The world's northernmost university hospital and the clinical base of UiT; The Arctic University of Norway; Phase II–IV across cardiovascular, oncology, pulmonology, and Arctic medicine; base institution for the Tromsø Study (45,000+ participants followed since 1974; one of the world's longest-running cardiovascular and population health cohort studies); specialist in circumpolar health, seasonal light variation physiology, and cold exposure medicine; research niches with no comparable institutional depth at any more southerly European site. |
| 08 | Stavanger University Hospital | Stavanger | Southwestern Norway's university hospital and one of Norway's most distinctive research sites for occupational health and cardiovascular medicine; University of Stavanger affiliate; Phase II–IV across cardiovascular, gastroenterology, and internal medicine; geographically co-located with Norway's petroleum industry hub; creating an exceptional occupational health and offshore medicine investigator community whose expertise in cardiovascular risk factors in extreme-environment working populations has no parallel in Scandinavian academic medicine. |
| 09 | Vestre Viken Hospital Trust | Drammen | The hospital trust serving the Viken region west of Oslo; Phase II–III across cardiovascular disease, oncology, and internal medicine; serves a large suburban Oslo metropolitan population that provides geographic enrollment coverage for sponsors seeking Oslo-proximate patients beyond the OUS and AHUS networks; active in national oncology and cardiovascular trial networks with growing Phase II–III commercial portfolio. |
| 10 | Sørlandet Hospital | Kristiansand | Southern Norway's primary hospital trust serving Aust-Agder and Vest-Agder counties; Phase II–III across cardiovascular, oncology, and internal medicine; an important southern Norwegian node for multi-site trial designs requiring geographic coverage across Norway beyond the Oslo-Bergen-Trondheim corridor; the southern Norwegian patient population's distinct coastal and maritime lifestyle exposure patterns are of interest for cardiovascular and respiratory epidemiological sub-studies. |
| 11 | Diakonhjemmet Hospital | Oslo | A major Oslo teaching hospital and one of Norway's most research-active private (diaconal) hospitals; University of Oslo affiliate; Phase II–IV with particular depth in rheumatology; the Department of Rheumatology here is one of Norway's leading rheumatology research centres and the institutional home of the NOR-DMARD registry (Norwegian Disease-Modifying Anti-Rheumatic Drug registry); an important site for sponsors developing biologics and small molecules in rheumatoid arthritis, psoriatic arthritis, and inflammatory joint disease indications in the Norwegian market. |
| 12 | Innlandet Hospital Trust | Hamar | The hospital trust serving the Innlandet (Hedmark and Oppland) inland region of Norway; Phase II–III across cardiovascular, mental health, and internal medicine; serves a large agricultural and rural population with distinctive occupational exposure patterns relevant for occupational health, respiratory, and cardiovascular research; an important node for sponsors seeking broad Norwegian geographic enrollment coverage in multi-site designs requiring inland population access beyond the coastal university hospital corridor. |
Norway's dedicated national cancer centre and one of Scandinavia's most internationally recognised oncology research institutions; University of Oslo Faculty of Medicine affiliate; Phase I–IV across solid tumours, haematologic malignancies, and radiotherapy-combined indications; houses Norway's primary Phase I oncology unit and the national tumour biobank; one of the founding members of the EORTC network and a longstanding active participant in international oncology cooperative groups; the institutional anchor of Norwegian oncology's global research standing.
Norway's national referral hospital for transplantation, rare diseases, congenital conditions, and specialist surgical procedures; University of Oslo affiliate; Phase II–IV with exceptional depth in solid organ transplantation pharmacology, paediatric rare diseases, congenital cardiac conditions, and haematological malignancies requiring bone marrow transplantation; houses the national paediatric hospital (Rikshospitalet Barneklinikken); a critical site for sponsors in orphan drug development requiring Norway's population-based rare disease patient identification infrastructure.
Oslo University Hospital's primary major general academic campus, covering a broad multispecialty research portfolio; University of Oslo affiliate; Phase II–IV across cardiovascular, neurology, psychiatry, emergency medicine, and internal medicine; home of NORMENT (Norwegian Centre for Mental Disorders Research); one of Europe's leading psychiatric genetics and CNS drug development research centres; the largest clinical trial volume among Oslo University Hospital's campuses for general therapeutic area programs.
One of Norway's largest hospitals, serving the Akershus county population immediately surrounding Oslo and one of the most research-active non-capital university hospitals in the country; University of Oslo affiliate; Phase II–IV across oncology, cardiovascular, endocrinology, and internal medicine; a rapidly growing Phase II–III commercial portfolio reflecting sustained investment in research infrastructure; important complement to Oslo University Hospital for sponsors seeking Oslo-region patient volume beyond the three OUS campuses.
Western Norway's premier academic hospital and the primary clinical base of the University of Bergen Faculty of Medicine; Phase I–IV across oncology, neurology; particularly multiple sclerosis; haematology, cardiovascular, and transplantation medicine; one of Norway's top two MS research centres with a large, well-characterised MS patient cohort; active EORTC and international cooperative group participation; home of the K.G. Jebsen Centres for MS Research and for Brain Tumours reflecting Bergen's particular specialist research depth in neurological oncology.
Central Norway's university hospital and the clinical base of NTNU Faculty of Medicine and Health Sciences; Phase II–IV across cardiovascular, oncology, neurology, endocrinology, and psychiatry; uniquely positioned as the anchor institution for the HUNT Study; giving St. Olavs investigators access to longitudinal data and biological samples from 229,000+ Trøndelag region participants for biomarker sub-studies, pharmacogenomics programs, and population-linked outcome ascertainment that is unmatched at any other Scandinavian clinical research site.
The world's northernmost university hospital and the clinical base of UiT; The Arctic University of Norway; Phase II–IV across cardiovascular, oncology, pulmonology, and Arctic medicine; base institution for the Tromsø Study (45,000+ participants followed since 1974; one of the world's longest-running cardiovascular and population health cohort studies); specialist in circumpolar health, seasonal light variation physiology, and cold exposure medicine; research niches with no comparable institutional depth at any more southerly European site.
Southwestern Norway's university hospital and one of Norway's most distinctive research sites for occupational health and cardiovascular medicine; University of Stavanger affiliate; Phase II–IV across cardiovascular, gastroenterology, and internal medicine; geographically co-located with Norway's petroleum industry hub; creating an exceptional occupational health and offshore medicine investigator community whose expertise in cardiovascular risk factors in extreme-environment working populations has no parallel in Scandinavian academic medicine.
The hospital trust serving the Viken region west of Oslo; Phase II–III across cardiovascular disease, oncology, and internal medicine; serves a large suburban Oslo metropolitan population that provides geographic enrollment coverage for sponsors seeking Oslo-proximate patients beyond the OUS and AHUS networks; active in national oncology and cardiovascular trial networks with growing Phase II–III commercial portfolio.
Southern Norway's primary hospital trust serving Aust-Agder and Vest-Agder counties; Phase II–III across cardiovascular, oncology, and internal medicine; an important southern Norwegian node for multi-site trial designs requiring geographic coverage across Norway beyond the Oslo-Bergen-Trondheim corridor; the southern Norwegian patient population's distinct coastal and maritime lifestyle exposure patterns are of interest for cardiovascular and respiratory epidemiological sub-studies.
A major Oslo teaching hospital and one of Norway's most research-active private (diaconal) hospitals; University of Oslo affiliate; Phase II–IV with particular depth in rheumatology; the Department of Rheumatology here is one of Norway's leading rheumatology research centres and the institutional home of the NOR-DMARD registry (Norwegian Disease-Modifying Anti-Rheumatic Drug registry); an important site for sponsors developing biologics and small molecules in rheumatoid arthritis, psoriatic arthritis, and inflammatory joint disease indications in the Norwegian market.
The hospital trust serving the Innlandet (Hedmark and Oppland) inland region of Norway; Phase II–III across cardiovascular, mental health, and internal medicine; serves a large agricultural and rural population with distinctive occupational exposure patterns relevant for occupational health, respiratory, and cardiovascular research; an important node for sponsors seeking broad Norwegian geographic enrollment coverage in multi-site designs requiring inland population access beyond the coastal university hospital corridor.
These are the primary regulatory, academic, and industry bodies shaping Norway's clinical research ecosystem.
Norway's national competent authority for pharmaceutical regulation and clinical trial oversight; implements EU pharmaceutical directives through the EEA Agreement with regulatory standards equivalent to EU member state NCAs; active participant in EMA scientific committee processes; responsible for clinical trial authorization, GCP inspection, and pharmacovigilance; Norwegian trial data generated under NoMA oversight is accepted in EU regulatory submissions, making Norwegian sites directly compatible with European development programs.
Norway's seven regionally distributed scientific ethics committees providing ethics review for all medical and health research; operated through a coordinated national REK portal enabling consistent review standards across all regions; responsible for protecting research participants in Norway in line with the Declaration of Helsinki and Norwegian Health Research Act; for multi-site Norwegian trials, a single REK submission can cover sites across multiple regions under the national coordination framework.
Norway's national public health institute and the custodian of the national health register infrastructure; including the Norwegian Cancer Registry (since 1953), Cause of Death Registry (since 1951), Norwegian Prescription Database (since 2004), and Medical Birth Registry (since 1967); all linked through the fødselsnummer system; provides the data access framework for research applications to Norwegian health registers, enabling register-based outcome ascertainment for clinical trials and pharmacoepidemiological sub-studies.
Norway's largest and most internationally prominent medical faculty; affiliated with Oslo University Hospital across all three major campuses (Radiumhospitalet, Rikshospitalet, Ullevål); the primary driver of the national investigator pipeline and Norway's most prolific producer of internationally published clinical research; partners with major international pharmaceutical companies in oncology, neuroscience, and cardiovascular disease; deep connections to Nordic collaborative research networks and major EU-funded research consortia.
The research hub of the Trøndelag Health Study (HUNT); one of the world's largest and most complete population health studies, with 229,000+ participants from successive cohort waves since 1984, including comprehensive cardiovascular measurements, biological samples, genetic data, and questionnaire-based lifestyle information; the HUNT biobank enables population-linked biomarker research, pharmacogenomic sub-studies, and Mendelian randomisation analyses that are available to sponsors through appropriate research partnership and ethics approval frameworks.
Western Norway's major medical faculty, affiliated with Haukeland University Hospital and driving the Bergen-region investigator pipeline; internationally recognised for MS research, neuro-oncology, and marine/nutritional epidemiology; home of the Bergen cohort studies including the Bergen COPD Cohort Study; active in European and international cooperative research groups in multiple sclerosis, inflammatory diseases, and brain tumours.
The world's northernmost medical faculty, driving the investigator pipeline for the University Hospital of North Norway and the Tromsø Study cohort; internationally recognised for Arctic medicine, circumpolar health, cardiovascular epidemiology, and the unique physiological research enabled by Norway's extreme northern latitude; the Tromsø Study; 45,000+ participants followed since 1974; is a foundational resource for cardiovascular, metabolic, and environmental health research available to sponsors partnering with UiT investigators.
Global CRO with Norwegian operations covering Phase I–IV trial management across oncology, MS, cardiovascular, and rare disease indications; NoMA regulatory submission expertise and REK ethics application support; site monitoring and data management across Oslo University Hospital, Haukeland, St. Olavs, and the broader Norwegian university hospital network; register data linkage support for outcome ascertainment sub-studies through the fødselsnummer infrastructure.
International CRO with Norwegian operations managing Phase II–IV MS, oncology, and cardiovascular programs; established investigator relationships at Oslo University Hospital, Haukeland University Hospital, and St. Olavs Hospital; specialist MS trial capability leveraging Norway's exceptional patient concentration and the Haukeland/Oslo MS investigator community; deep NoMA regulatory expertise supporting EEA-aligned submissions compatible with EU member state CTIS frameworks.
Global CRO with Norwegian operations providing Phase II–III trial management and regulatory strategy; NoMA submission expertise for oncology, CNS, and rare disease programs; established site networks across Oslo University Hospital, Haukeland, and Akershus University Hospital; supports sponsors adding Norwegian sites to existing Scandinavian or Nordic trial portfolios or designing Norwegian-anchored multi-site programs leveraging the HUNT Study biobank and Norwegian MS patient depth.
Norway's primary governmental research funding body, channelling petroleum revenues into biomedical, clinical, and translational research programs across all Norwegian universities and hospital trusts; provides substantial co-funding for international research partnerships through programs such as FRIPRO (fundamental research) and the Clinical Research and Health Registries programs; a key enabler for public-private partnership structures that allow international sponsors to co-invest with Norwegian government research funding in register-linked population health and clinical trial programs.
Norway gives sponsors a distinctive Nordic research environment built on EEA aligned regulation, national health registers, strong university hospitals, deep MS expertise, the HUNT Study, and long term cancer registry data. For programs that need reliable follow up, registry linked outcomes, and specialist neurological, oncology, cardiovascular, or Arctic medicine capability, Norway can be a highly strategic clinical trial market.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.